This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

OMS616

Omeros Corporation

Drug Names(s): OMS616

Description: This compound is a recombinant human anti-plasmin protein.

Deal Structure: On December 14, 2010, Omeros entered into a license agreement with The Regents of the University of California pursuant to which the Company received an exclusive license to a series of antifibrinolytic agents claimed in certain patents owned by The Regents in exchange for the Company's agreement to make royalty and development milestone payments.


OMS616 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug